Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘anti-PD1 therapy’

A couple of years ago one of the controversial topics in the Immuno-Oncology space centered around pseudoprogression and whether it was real or not, leading to the development of immune related adverse event (iras) criteria.

Fast forward to Spring 2017 and a new controversy has sprung up, which is focused upon hyperprogression following several publications on the topic.  

It’s a rather nasty situation where people with cancer can rapidly deteriorate and progress faster than normally would be expected.

Is this down to something real associated with the immunotherapy, however, or simply a function of a sick patient taking an inert therapy that takes a while to have an impact?

Strong opinions on the topic have inevitably arose, with different views on whether the phenomenon is real or not and how we could go about assessing and measuring it.  It’s an interesting debate that’s well worth following…

To learn more, subscribers can log-in to read our latest insights or you can gain access to BSB Premium Content.

This content is restricted to subscribers

We’re continuing our coverage of highlights from the inaugural ASCO-SITC Clinical Immuno-Oncology Symposium with a look at a novel way to potentially improve the efficacy of checkpoint inhibitors.

It’s not something we’ve previously written about, nor is it included in the recent Chen & Mellman Nature paper that discusses “factors that influence the cancer-immune set point.

So there’s a good chance it may not be on your radar either.

Given the commercial stakes at play in improving checkpoint efficacy, combination strategies that could have an impact are worth thinking about when it comes to designing clinical trials.

Subscribers can login to read more

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!